Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Passaro A, Attili I, Morganti S, Del Signore E, Gianoncelli L, Spitaleri G, et al. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: a critical review of published data. Cancer Treat Rev. 2020;89: 102085.

Article  CAS  PubMed  Google Scholar 

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358–76.

Article  CAS  PubMed  Google Scholar 

Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res. 2015;5:2892–911.

PubMed  PubMed Central  Google Scholar 

Nagasaka M, Zhu VW, Lim SM, Greco M, Wu F, Ou S-HI. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16:740–63.

Remon J, Steuer CE, Ramalingam SS, Felip E. Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. Ann Oncol. 2018;29:i20–7.

Article  CAS  PubMed  Google Scholar 

Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339–57.

Article  CAS  PubMed  Google Scholar 

Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376:629–40.

Article  CAS  PubMed  Google Scholar 

Ahn M-J, Tsai C-M, Shepherd FA, Bazhenova L, Sequist LV, Hida T, et al. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019;125:892–901.

Article  CAS  PubMed  Google Scholar 

Soria J-C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378:113–25.

Article  CAS  PubMed  Google Scholar 

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41–50.

Article  CAS  PubMed  Google Scholar 

Brody R, Zhang Y, Ballas M, Siddiqui MK, Gupta P, Barker C, et al. PD-L1 expression in advanced NSCLC: insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15.

Article  PubMed  Google Scholar 

Chen N, Fang W, Zhan J, Hong S, Tang Y, Kang S, et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-Driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J Thorac Oncol. 2015;10:910–23.

Article  CAS  PubMed  Google Scholar 

Akbay EA, Koyama S, Carretero J, Altabef A, Tchaicha JH, Christensen CL, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.

Article  CAS  PubMed  Google Scholar 

Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma. J Thorac Oncol. 2017;12:878–83.

Article  PubMed  PubMed Central  Google Scholar 

Jiang X-M, Xu Y-L, Huang M-Y, Zhang L-L, Su M-X, Chen X, et al. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. Acta Pharmacol Sin. 2017;38:1512–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu Y, Xia L, Zhou J, Wang K, Zhang Y, Zhang C, et al. 147P PD-L1 expression influenced by osimertinib treatment in advanced EGFR T790M-positive non-small cell lung cancer patients. J Thorac Oncol. 2021;16:S778.

Article  Google Scholar 

Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2021;19:145.

Article  PubMed  PubMed Central  Google Scholar 

Lan B, Wang Y, Wu J, Wang K, Wang P. The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC. Med (Baltim). 2021;100: e27038.

Article  CAS  Google Scholar 

Su S, Dong Z-Y, Xie Z, Yan L-X, Li Y-F, Su J, et al. Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients With EGFR mutation. J Thorac Oncol. 2018;13:1668–75.

Article  PubMed  Google Scholar 

Hsu K-H, Huang Y-H, Tseng J-S, Chen K-C, Ku W-H, Su K-Y, et al. High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients. Lung Cancer. 2019;127:37–43.

Article  PubMed  Google Scholar 

Brown H, Vansteenkiste J, Nakagawa K, Cobo M, John T, Barker C, et al. Programmed cell death ligand 1 expression in untreated EGFR mutated advanced NSCLC and response to osimertinib versus comparator in FLAURA. J Thorac Oncol. 2020;15:138–43.

Article  CAS  PubMed  Google Scholar 

Hsu K-H, Tseng J-S, Yang T-Y, Chen K-C, Su K-Y, Yu S-L, et al. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep. 2022;12:9753.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiozawa T, Numata T, Tamura T, Endo T, Kaburagi T, Yamamoto Y, et al. Prognostic implication of PD-L1 expression on osimertinib treatment for EGFR-mutated non-small cell lung cancer. Anticancer Res. 2022;42:2583–90.

Article  PubMed  Google Scholar 

Lababede O, Meziane MA. The eighth edition of TNM staging of lung cancer: reference chart and diagrams. The Oncologist. 2018;23:844–8.

Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, et al. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res. 2021;10(2):699–711.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang C-Y, Liao W-Y, Ho C-C, Chen K-Y, Tsai T-H, Hsu C-L, et al. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer Oxf Engl. 1990;2020(124):110–22.

Google Scholar 

Fu F, Deng C, Sun W, Zheng Q, Jin Y, Li Y, et al. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer. Respir Res. 2022;23:302.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Prince EA, Sanzari JK, Pandya D, Huron D, Edwards R. Analytical concordance of PD-L1 assays utilizing antibodies from FDA-approved diagnostics in advanced cancers: a systematic literature review. JCO Precis Oncol. 2021;953–73.

Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol. 2017;12:208–22.

Article  PubMed  Google Scholar 

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer. J Clin Oncol. 2018;36:3290–7.

Article  CAS  Google Scholar 

Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, et al. UNcommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-line setting (UNICORN). J Thorac Oncol. 2023;18:169–80.

Article  CAS  PubMed  Google Scholar 

Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38:488–95.

Article  CAS  PubMed